Simulations Plus, Inc. (NASDAQ: SLP) is a company that specializes in providing software and consulting services for pharmaceutical research and development. The company is known for its advanced simulation and modeling software, which aids in drug discovery and development processes. SLP operates in a competitive market, with other players like Certara and Schrödinger offering similar services.
On July 14, 2025, KeyBanc downgraded SLP from an Overweight rating to a Sector Weight rating. This downgrade coincided with the company's Q3 2025 earnings conference call, which featured CEO Shawn M. O'Connor and EVP & CFO William Frederick. The stock price at the time of the downgrade was $17.47, as highlighted by Seeking Alpha.
Despite the downgrade, SLP's stock price showed resilience, experiencing a price change of $0.51, which is an increase of approximately 3.01%. The stock fluctuated between a low of $16.94 and a high of $17.585 on the same day. This indicates some level of investor confidence despite the downgrade.
Over the past year, SLP's stock has seen significant volatility, with a high of $44.33 and a low of $16.72. The current market capitalization of SLP is approximately $351.3 million, and the trading volume on the day of the downgrade was 1,414,365 shares. This level of trading activity suggests that the market is actively engaging with the stock, possibly in response to the recent earnings call and downgrade.
